SCHEMBL7902899

SCHEMBL7902899

COC(=N)c1ccc(NC(=O)[C@H](O)[C@H]2OCCN(Cc3ccc(OC)cc3)C2=O)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F9 P00740 6/20 0.70
HIF1A Q16665 1/20 0.48
EPAS1 Q99814 1/20 0.48
KMT2A Q03164 5/20 0.44
MAPT P10636 1/20 0.44
PKM P14618 1/20 0.43
MEN1 O00255 3/20 0.42
KDM4E B2RXH2 1/20 0.42
GALR3 O60755 1/20 0.42
LMNA P02545 1/20 0.42
HSD17B10 Q99714 1/20 0.41
TNF P01375 1/20 0.41
NOD2 Q9HC29 1/20 0.41
NOD1 Q9Y239 1/20 0.41
HDAC1 Q13547 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12546512 0.93 F9 (0.70) F9HIF1AEPAS1KMT2AMAPT
SCHEMBL1947228 0.92 F9 (0.82) F9HIF1AEPAS1KMT2AMAPT
Hydrochloric Acid SCHEMBL1949875 0.91 F9 (0.81) F9HIF1AEPAS1KMT2AMAPT
SCHEMBL1949460 0.86 F9 (0.60) F9HIF1AEPAS1KMT2AMAPT
SCHEMBL12546714 0.86 F9 (0.60) F9HIF1AEPAS1KMT2AMAPT
SCHEMBL1949463 0.86 F9 (0.60) F9HIF1AEPAS1KMT2AMAPT
SCHEMBL1947789 0.82 F9 (1.00) F9MAPTSMN1; SMN2
Hydrochloric Acid SCHEMBL17237638 0.81 F9 (0.98) F9MAPTSMN1; SMN2
SCHEMBL17244490 0.81 F9 (0.85) F9
SCHEMBL1438329 0.81 F9 (0.54) F9HIF1AEPAS1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2373634-B1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS MOCHIDA PHARM CO LTD (JP) 2015-11-11 EP disclosed
US-8987242-B2 Morpholinone compounds as factor IXA inhibitors MERCK SHARP & DOHME CORP. (US) 2015-03-24 US disclosed
US-8642582-B2 Morpholinone compounds as factor IXa inhibitors MERCK SHARP & DOHME CORP. (US) 2014-02-04 US disclosed
US-20110135650-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-06-09 US disclosed
WO-2010065717-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110135650-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS SERPINC1, F9, F8 F9 2/4885HIF1A 923/4885EPAS1 2412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.